Puna on for Ami Fadia's questions to Day One Biopharmaceuticals Inc (DAWN) leadership • Q2 2025
Question
On behalf of Needham & Company, Puna requested more detail on the assumptions for new patient additions versus discontinuations within the 2025 guidance, the gross-to-net percentage for Q2, and the development progress of the ADC Day301 program.
Answer
CFO Charles York reiterated that guidance assumes continued persistence, steady new patient starts, channel stock of 2-4 weeks, and a gross-to-net range of 12%-15%. Head of R&D Michael Vasconcelles reported that the Day301 Phase 1 dose escalation is progressing as expected and that the company is confident in its innovative molecule targeting PTK7.